Lynparza Tablet (Olaparib)
Lynparza selectively targets cancer cells with specific genetic mutations, such as BRCA1, BRCA2, and HRR gene mutations. By inhibiting the PARP enzyme, Lynparza hampers the cancer cells' ability to repair DNA damage, leading to cell death and tumor regression.
Lynparza (Olaparib) is a cutting-edge, FDA-approved oral medication designed to treat specific cancers by targeting the PARP enzyme responsible for repairing cancer cell DNA. Ideal for patients with BRCA-mutated ovarian, breast, pancreatic, and prostate cancers, Lynparza works by preventing cancer cells from repairing themselves, leading to their destruction.
This 150mg film-coated tablet is taken twice daily and offers a convenient, effective treatment option for those seeking advanced cancer care. Trusted globally and manufactured by AstraZeneca, Lynparza ensures a high standard of quality and safety.
Key benefits:
- Targets and kills cancer cells with BRCA or HRR mutations
- FDA-approved for multiple cancer types
- Oral administration for ease and convenience
- Available for purchase online with reliable delivery
Precautions of Lynparza Tablet:
Pregnancy and Breastfeeding: Lynparza can harm an unborn baby. Women should use effective contraception during treatment and for at least 6 months after the last dose. Men with female partners who can become pregnant should also use contraception during treatment and for at least 3 months after the last dose.
Blood Disorders: Regular blood tests are recommended to monitor blood cell counts.
Kidney and Liver Function: Dose adjustments may be necessary for patients with impaired kidney or liver function.
Uses of Lynparza Tablet:
Treatment of advanced or recurrent ovarian cancer with BRCA1 or BRCA2 mutations, especially after platinum-based chemotherapy.
Management of HER2-negative breast cancer in patients with inherited BRCA mutations.
Therapy for pancreatic cancer with BRCA mutations following first-line platinum-based chemotherapy.
Treatment of metastatic castration-resistant prostate cancer in patients with BRCA or homologous recombination repair (HRR) gene mutations.
Side Effects of Lynparza Tablet:
Common side effects include nausea, fatigue, anemia, and decreased appetite. Serious side effects may include bone marrow problems, lung issues, and blood clots. Patients should seek immediate medical attention if they experience symptoms such as shortness of breath, chest pain, or unusual bruising.
FAQs of Lynparza Tablet:
1. Is Lynparza a chemotherapy drug?
No, Lynparza is a targeted therapy that works by inhibiting the PARP enzyme, which is involved in DNA repair in cancer cells. Unlike traditional chemotherapy, it specifically targets cancer cells with certain genetic mutations.
2. How long will I need to take Lynparza?
The duration of treatment varies depending on the type of cancer and individual patient factors. For ovarian cancer, treatment may continue for up to 2 years. For other cancers, the treatment duration will be determined by the healthcare provider based on the patient's response to therapy.
3. Can I take Lynparza with other medications?
Lynparza may interact with other medications. It is important to inform your healthcare provider about all other medications you are taking, including over-the-counter drugs and supplements, to avoid potential interactions.
Interactions of Lynparza Tablet:
Avoid concomitant use with strong or moderate CYP3A inhibitors.
Grapefruit and grapefruit juice may increase the blood levels of Lynparza and should be avoided.
| Manufacturer | : | AstraZeneca, India |
| Trade Name | : | |
| Generic Search | : | Olaparib |
| Strength | : | 100mg, 150mg |
Latest Products
